Renal Cell Carcinoma with Clear Cell Papillary Features: Perspectives of a Differential Diagnosis.
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ analysis
Carcinoma, Papillary
/ diagnosis
Carcinoma, Renal Cell
/ diagnosis
DNA Methylation
/ genetics
Diagnosis, Differential
Female
Humans
Kidney Neoplasms
/ diagnosis
Male
Middle Aged
Retrospective Studies
Von Hippel-Lindau Tumor Suppressor Protein
/ genetics
Clear cell carcinoma
Clear cell papillary carcinoma
Cytokeratin 7-positivity
Differential diagnosis
VHL gene
Journal
Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
22
05
2019
accepted:
01
10
2019
pubmed:
28
10
2019
medline:
7
4
2021
entrez:
28
10
2019
Statut:
ppublish
Résumé
Thirty-one cases of low-grade renal cell carcinoma (RCC) with clear cells and tubulopapillary/papillary architecture were analyzed retrospectively with immunohistochemical and genetic markers to gain more experience with the differential diagnosis of such cases. All samples coexpressed CK7 and CA9; the TFE3 or TFEB reactions were negative; the CD10 and the AMACR stainings were negative in 27 cases and 30 cases, respectively. The FISH assays for papillary RCC, available in 27 cases, and deletion of chromosome 3p, available in 29 cases, gave negative results. The results for 3p deletion, VHL gene mutation or VHL gene promoter region hypermethylation testing, along with the diffuse CD10-positivity in 2 cases confirmed 21 cases as clear cell papillary RCC (CCPRCC; CK7+, CA9+; no 3p loss, no VHL abnormality) and 10 cases as clear cell RCC (CCRCC; CK7+, CA9+; no 3p loss, VHL abnormality mutation/hypermethylation present). In CCPRCCs, the representative growth pattern was branching tubulo-acinar, commonly accompanied by cyst formation. The linear nuclear arrangement or cup-shaped staining of CA9 did not necessarily indicate CCPRCC, and the absence of these did not exclude the diagnosis of CCPPRC. One tumor infiltrated the renal sinus; the others exhibited pT1 stage; and metastatic outcome was not recorded. The CCRCC cases were in pT1 stage; 6 exhibited cup-shaped staining of CA9, and 1 displayed lymph node metastasis at the time of surgery. Distant metastatic disease was not observed. In summary, the VHL abnormalities distinguished the subset of CCRCC with diffuse CK7-positivity and no 3p loss from cases of CCPRCC.
Identifiants
pubmed: 31656019
doi: 10.1007/s12253-019-00757-3
pii: 10.1007/s12253-019-00757-3
pmc: PMC7297853
doi:
Substances chimiques
Biomarkers, Tumor
0
Von Hippel-Lindau Tumor Suppressor Protein
EC 2.3.2.27
VHL protein, human
EC 6.3.2.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1767-1776Références
Rare Tumors. 2017 Mar 24;9(1):6550
pubmed: 28458790
Appl Immunohistochem Mol Morphol. 2018 Mar;26(3):192-197
pubmed: 29084058
Virchows Arch. 2014 Jul;465(1):89-96
pubmed: 24838683
Am J Surg Pathol. 2013 Oct;37(10):1469-89
pubmed: 24025519
Am J Surg Pathol. 2016 Feb;40(2):141-54
pubmed: 26752401
Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6
pubmed: 8790415
Pathol Oncol Res. 2018 Jul;24(3):447-456
pubmed: 28695322
Hum Pathol. 2009 Mar;40(3):425-9
pubmed: 18789480
Mod Pathol. 2011 Sep;24(9):1207-20
pubmed: 21602815
Pathology. 2008 Aug;40(5):481-6
pubmed: 18604734
Ann Diagn Pathol. 2000 Oct;4(5):311-5
pubmed: 11073338
Pathol Res Pract. 1993 Sep;189(8):951-6; discussion 957-9
pubmed: 8302716
Virchows Arch. 2009 Jun;454(6):719
pubmed: 19471960
Am J Surg Pathol. 2015 Jul;39(7):873-88
pubmed: 25970682
Pathol Res Pract. 2014 Apr;210(4):234-41
pubmed: 24485757
Arch Pathol Lab Med. 2012 Apr;136(4):391-9
pubmed: 22458901
Hum Pathol. 2013 Jul;44(7):1412-20
pubmed: 23434146
Am J Surg Pathol. 2015 Nov;39(11):1502-10
pubmed: 26457355
Virchows Arch. 2016 Jul;469(1):81-91
pubmed: 27173781
Adv Anat Pathol. 2011 Mar;18(2):120-32
pubmed: 21326010
Int J Clin Exp Pathol. 2014 Oct 15;7(11):7312-8
pubmed: 25550767
Hum Pathol. 2014 Jan;45(1):59-64
pubmed: 24182559
Am J Surg Pathol. 2006 Feb;30(2):141-53
pubmed: 16434887
Int J Cancer. 2008 Aug 1;123(3):569-76
pubmed: 18478571
Am J Surg Pathol. 2008 Aug;32(8):1239-45
pubmed: 18594469
Am J Surg Pathol. 2013 Aug;37(8):1131-9
pubmed: 23648463
Am J Surg Pathol. 2015 Dec;39(12):1621-34
pubmed: 26426379
EJIFCC. 2006 Mar 20;17(1):12-16
pubmed: 29795717
J Neuropathol Exp Neurol. 2004 Apr;63(4):314-22
pubmed: 15099021
Mod Pathol. 2013 May;26(5):697-708
pubmed: 23238627
Am J Surg Pathol. 2010 Nov;34(11):1608-21
pubmed: 20924276
Am J Surg Pathol. 2006 Nov;30(11):1372-81
pubmed: 17063076
Mod Pathol. 2015 Jun;28(6):845-853
pubmed: 25676555
Eur Urol. 2016 Jul;70(1):106-119
pubmed: 26996659
Hum Pathol. 2014 Sep;45(9):1966-72
pubmed: 25081542
Am J Surg Pathol. 2008 Dec;32(12):1780-6
pubmed: 18779729
Mod Pathol. 2014 May;27(5):765-74
pubmed: 24201123
Histopathology. 2011 Jun;58(7):1064-71
pubmed: 21707708
Ann Diagn Pathol. 2016 Apr;21:59-64
pubmed: 26897641
Am J Surg Pathol. 2015 Jul;39(7):889-901
pubmed: 25970683